• Crohn's disease;
  • inflammatory bowel disease;
  • ischaemia;
  • microvasculature;
  • ulcerative colitis;
  • vasculature


  1. Top of page
  2. Abstract
  3. Introduction
  4. Evidence for hyperaemia in the chronically inflamed IBD intestine
  5. Evidence for ischaemia in the chronically inflamed IBD intestine
  6. Unifying hypothesis for altered vascular physiology in IBD
  7. References

This review has focused on evidence regarding intestinal perfusion of inflammatory bowel disease (IBD). Basic investigation has defined an altered microvascular anatomy in the affected IBD bowel, which corresponds with diminished mucosal perfusion in the setting of chronic, long-standing inflammation. Diminished perfusion is linked to impaired wound healing, and may contribute to the continued refractory mucosal damage, which characterizes IBD. Alterations in vascular anatomy and physiology in IBD suggests additional possible mechanisms by which micro-vessels may contribute to the initiation and perpetuation of IBD. This begs the following questions: will angiogenesis within the gut lead to sustained inflammation, does the growing vasculature generate factors that transform the surrounding tissue and does angiogenesis generate vascular anastomosis within the gut, with shunting of blood away from the mucosal surface, impairment of metabolism and potentiation of gut damage? Further studies are required to define the mechanisms that underlie the vascular dysfunction and its role in pathophysiology of IBD.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Evidence for hyperaemia in the chronically inflamed IBD intestine
  5. Evidence for ischaemia in the chronically inflamed IBD intestine
  6. Unifying hypothesis for altered vascular physiology in IBD
  7. References

Inflammation is a response of vascularized tissues to sublethal injury where immunological, defensive and reparative mechanisms are activated in an orchestrated response to restore tissue homeostasis [1,2]. It is designed to destroy or inactivate invading pathogens, remove waste and cellular debris and permit restoration of normal function, either through resolution or repair. This reaction may trigger a systemic response such as fever, leukocytosis, protein catabolism and altered hepatic synthesis of plasma proteins, such as C-reactive protein [3]. Inflammation can be classified according to duration as either acute or chronic, where the vasculature plays integral roles in both processes [3]. Acute inflammation is characterized by a classic vascular response involving tissue hyperaemia resulting from dilation of small blood vessels followed by fluid and granulocyte accumulation at the injured site. In contrast, chronic inflammation is marked by tissue infiltration with macrophages and lymphocytic cells. The role of the micro-vasculature in altered leukocyte recruitment is perhaps the best characterized aspect of micro-vascular physiology in chronic inflammation, which may lead to a functional but morphologically altered organ over time.

A highly controversial concept regarding the micro-vascular contribution to chronic inflammation involves the pathophysiology of tissue perfusion and blood flow. As opposed to acute inflammation, where tissue hyperaemia and increased vascular perfusion play a critical role in essentially all aspects of the response, there is compelling data suggesting that both increased tissue blood flow (i.e. hyperaemia) as well as impaired, diminished blood flow (i.e. ischaemia) can be identified within chronically inflamed tissue.

Inflammatory bowel diseases (IBD: Crohn's disease, ulcerative colitis) are lifelong disorders characterized by chronic inflammatory damage in the gastrointestinal tract. Although the etiopathogenesis of IBD has not been defined and the majority of research has focused on an inappropriate innate and acquired immune response to enteric bacterial and potentially other antigens, the vasculature is also considered to play a key role in the disease process. Data demonstrating increased perfusion of the mesenteric vasculature in active, fulminant colitis has been described. In contrast, diminished vascular perfusion of the mucosal surfaces and the arterioles in and below the mucosa has also been shown in patients with longstanding disease.

This article will review data demonstrating the vascular perfusion changes and IBD and attempt to reconcile the apparent conflict between simultaneous hyperaemia and ischaemia with a unifying hypothesis linking vascular perfusion abnormalities to the pathophysiology of IBD intestine.

Evidence for hyperaemia in the chronically inflamed IBD intestine

  1. Top of page
  2. Abstract
  3. Introduction
  4. Evidence for hyperaemia in the chronically inflamed IBD intestine
  5. Evidence for ischaemia in the chronically inflamed IBD intestine
  6. Unifying hypothesis for altered vascular physiology in IBD
  7. References

Surgical appearance of the intestine in IBD

Although considerable variation exists in the presentation of the disease in surgical specimens, Crohn's disease (CD) is often recognized solely by appearance of macroscopic lesions including mucosal ulceration and thickening of the bowel wall caused by inflammatory cell infiltration and oedema. Surgical assessment of the intestine in CD reveals that the mesentery is often thickened and stiff with hypertrophied white adipose tissue [4,5]. This fat wrapping correlates with the presence of underlying acute and chronic inflammation, in addition to transmural inflammation in the form of lymphoid aggregates [6]. It may extend from the mesenteric attachment and partially cover the small and/or large intestinal circumference, and is considered a reliable indicator for CD [7]. Furthermore, peroxisome proliferation activator receptor γ (PPARγ), a pivotal mediator in the regulation of adipose tissue homeostasis and lipogenesis, is found in increased amount in bowel from subjects with CD [8]. Adipocytes may participate in the inflammatory process of CD by producing tumour necrosis factor and other inflammatory and pro-angiogenic factors [8]. Neovascularization and micro-vascular hypertrophy of the serosal surfaces of the intestine may also be present in the absence of fat wrapping [6,9]. This angiogenic process will sometimes remain as the only indication of an area previously affected by CD, once the chronic inflammatory infiltrate has subsided. Although these abnormalities of mesenteric fat in CD have long been recognized their pathophysiologic relevance is still unknown [8]. Because the origin of the confined mesenteric fat hypertrophy in CD is not defined, it is tempting to speculate that a mesenteric over-expression of PPARγ is the origin of a localized fat wrapping hypertrophy and in turn increases tissue hyperaemia and augmented blood flow in IBD.

In contrast, the remodelled ulcerative colitis (UC) intestine mostly demonstrates mucosal and muscle layer changes that may lead to shortening and narrowing of the large bowel. However, fibrosis is uncommon and smooth strictures are rarely observed in long-standing chronic disease [10,11].

Early IBD-increased mucosal perfusion – intraoperative and endoscopic studies

The importance of the vascular system in intestinal physiology and homeostasis has prompted studies into potential vascular alterations in IBD. The characterization of intestinal blood flow in IBD has been completed using both direct and indirect methods of perfusion measurement. These methods include micro-sphere techniques, laser Doppler velocimetry, hydrogen clearance, and various spectroscopic procedures. Spectroscopic measurements have been more extensively used to measure perfusion in the abdomen and duodenum and suggest an increase in mucosal blood flow early on in IBD patients [12,13]. These findings have been confirmed by other studies utilising intra-operative isotope washout [14] as well as in vivo abdominal angiography. Hulten et al. demonstrated that in severe, acute UC and CD (i.e. initial presentation) there is tissue hyperaemia, intense hyper-vascularity, with significantly augmented blood flow compared with normal controls [14,15]. These early observations have been confirmed with subsequent endoscopic Doppler ultrasonography exhibiting an augmented blood flow only in acute disease and early phases of animal models of colitis [16].

Transabdominal ultrasound studies of gut perfusion in IBD patients

Several noninvasive techniques have been employed to assess gut blood flow in human subjects. Doppler ultrasonography (US) is a suitable non-invasive method for investigating splanchnic haemodynamics [17]. Previous studies have shown US to be accurate and reproducible in various pathophysiological conditions such as intestinal angina [18], portal hypertension [16] as well as in the diagnosis and follow ups of patients with IBD [17,19–24]. An advantage of US is its ability to enable visualization and location of transmural bowel inflammation in CD, discrimination of CD from UC, determination of the extent of the lesions and detection of complications such as strictures, fistulas and abscesses [19,20,25,26]. Bolondi et al. and others have demonstrated that patients with UC or CD have significantly higher portal and mesenteric venous outflow compared with healthy controls [19–22,27]. These findings are consistent with a hyperdynamic splanchnic circulation in active IBD.

Unfortunately, the technical and systematic problems of US are manifold. Major sources of error include incorrect positioning of the US probe, difficulty in obtaining an optimal angle of insonation and imprecise measurements of the lumen diameter, which may lead to the incorrect estimation of flow by greater than 25%[17]. Other non-technical limitations must also be considered. First, medications used in the treatment of IBD may exert changes in vascular physiology. Corticosteroids may increase not only systemic but also mesenteric vascular tone, thereby decreasing blood velocity and flow in the abdomen [28]. In contrast, posture-induced blood volume expansion has been shown to increase mesenteric blood flow in healthy controls [29]. Therefore, the net effect of steroids on mesenteric blood may be of minor importance, which is supported by observations that intra-arterial infusion of cortisol has no vaso-constricting or dilating effects in healthy subjects [30]. Second, splanchnic flow might be altered in patients with previous intestinal resection. After extended small bowel resection in animals, increased blood flow was observed in the ileum but not colon [31]. In contrast, human studies demonstrated decreased blood flow in the neo-terminal ileum after ileocolonic resection for CD compared with controls [32]. Third, active IBD bowel segments are thickened, oedematous, and therefore less mobile. These segments show reduced motility and compressibility and are painful on graded compression [33–36]. Finally, suboptimal distension of the colon, air in the colon or colonic contents can cause artifacts, thus hampering an accurate assessment of the bowel wall in ultrasound examinations.

Microbubble contrast enhancement of abdominal Doppler US in IBD

Limitations in the ability of traditional US to assess the micro-circulation has led to the development of new techniques in trans-abdominal US using intravenous microbubble contrast reagents (Levovist; galactose-based sonographic contrast agent; Schering AG, Berlin, Germany) [37]. Microbubbles interact with an ultrasound beam and resonate, producing harmonic enhanced signals. This agent is useful in detection of small vessel flow, especially in areas where the signal to noise ratio limits traditional US sensitivity and performance, including intracranial and deep abdominal examination [38]. Transabdominal Doppler sonography with Levovist increased the sonographic sensitivity from 70·9% to 96·7% and allowed for the differentiation of specific subsets of CD patients (i.e. active, fibrotic and relapsing diseases). Sabatino et al. conducted the first study using microbubble contrast enhanced US as a diagnostic modality for CD [39] and identified high signal intensity in basal Doppler, which was further increased after Levovist injection. Most of these CD patients had abnormal bowel wall thickness. This finding was reinforced by after achieving remission a significant reduction in bowel wall thickness was observed. In addition they reported on a particular subset of patients who did not show any basal Doppler signal, but enhanced signal intensity with additional microbubble contrast. Overall, these findings have demonstrated increased intestinal perfusion and hyperaemia in the remodelled and thickened IBD intestine.

However, the description of increased Doppler US in CD patients with Levovist-contrast has not uniformly demonstrated all hyperaemia. First, patients with previous intestinal resection demonstrated a distinct low blood flow pattern to the neo-terminal ileum, compared with non-operated CD patients. Second, Doppler US studies specifically evaluating mucosal surfaces using an intraluminal approach, as opposed to the trans-abdominal approach, have demonstrated diminished perfusion in CD [32,40]. Third, the ultrasound observations which suggest enhanced blood flow in CD patients may actually reflect the thickened CD intestine and its associated serosal fat wrapping with enhanced serosal vascularity [4,5,7,41]. These studies suggested that a simple correlation with enhanced Doppler US signal using Levovist and CD does not exist, but must take into account the location of the probe (mucosal vs. transabdominal) as well as the stage of the disease.

Ultrasound correlation with disease activity in IBD

In IBD, assessment of disease activity and prediction of relapse are of major clinical importance. There are few studies correlating endoscopic findings with US findings. Futagami et al. found a significant correlation between an US index and endoscopic/radiological score in patients with CD, whilst a weak correlation was found between disease activity index and biological indices of inflammation [42]. These data are of great value in the ongoing assessment and treatment of IBD patients. Furthermore, differentiation between UC and CD with US is controversial. Most investigators have not observed any specific US pattern, but others have reported that the US pattern can differentiate between CD and UC [26,35,43]. Some authors report lower accuracy for US in UC than CD, whereas some other studies have demonstrated better results in UC than in CD [44–46]. In general, ultrasound is more accurate in evaluation of UC than CD, which may be explained by different segmental distribution of involvement in UC vs. CD.

Published data correlating ultrasound findings and clinical disease activity indices or other biologic parameters of disease activity in IBD have also demonstrated conflicting results. Haber et al. demonstrated that bowel wall thickness, as measured by US, is related to disease activity [45] and suggests that US is an accurate and easy, non-invasive method for monitoring the intestinal inflammatory process of the CD patient after the diagnosis is established and treatment initiated [47]. Kettretz et al. found a significant correlation between bowel wall thickness measured by US and abdominal pain score, or stool score, in children with UC but not in children with CD [48]. D’Arienzo et al. reported that the bowel wall thickness was the only parameter that could differentiate the activity of UC, which correlated significantly with a modified clinical endoscopic activity index of these patients [49]. In contrast, Mayer et al. and others demonstrated there was no correlation between the volume of inflamed bowel and clinical activity of IBD [42,50]. The above observations suggested that US measurements may evolve as a simple non-invasive method for monitoring the intestinal inflammatory process following IBD diagnosis and after treatment has been initiated, but further work is needed at this time.

Angiogenesis in IBD

Angiogenesis is defined as a growth of new capillary blood vessels from pre-existing vasculature [51]. This is of key importance in numerous physiologic and pathologic processes, including embryogenesis, tissue growth, wound healing and the female reproductive cycle. Angiogenesis may also contribute to the pathology of diseases such as cancer, psoriasis, tissue damage during reperfusion following ischaemia or cardiac failure, diabetic retinopathy and chronic inflammatory diseases in joints or gut [52–55]. Inflammation may promote angiogenesis in a number of ways [53,56–60]. Inflammatory tissue is often hypoxic and hypoxia can induce angiogenesis through up-regulation of factors such as vascular endothelial growth factor, fibroblast growth factor-1, tumour necrosis factor α, hypoxia-inducible factor-1 and other factors [61–65]. Extravasated plasma fibrinogen can stimulate neovascularization [66–68]. Inflammatory cells such as macrophages, lymphocytes, mast cells and fibroblasts can stimulate vessel growth by producing angiogenic factors [69–73]. Increased blood flow itself may stimulate angiogenesis through shear stress on the endothelium [74–76].

Currently, evidence for the presence of angiogenesis in IBD is extremely limited. Indirect evidence clues that increased vascularization actually occur in the inflamed mucosa. Up-regulation of pro-angiogenic factors [77,78] is consistent with Doppler US findings of increased vessel density of acute inflamed bowel loops. However, as cautioned earlier, this may represent an increased density of the overlapping fat micro-vessels, not mucosal vessel proliferation. Recent studies by Danese and colleagues have demonstrated angiogenic activity in an animal model of IBD, with additional demonstration of angiogenic cytokines being released from tissue biopsies from IBD patient materials [79]. Further studies have suggested that the IL-10 knock-out mouse will demonstrate clinical improvement when treated with novel angiogenesis inhibitors, which have also demonstrated benefit in models of rheumatoid arthritis [79].

Direct evidence of angiogenesis in acute and chronic inflammation, particularly human inflammatory disease, remains limited, with a majority of data from rheumatoid arthritis where angiogenesis is felt to be a central component of pannus formation in the inflamed synovium [80]. To date, the available data suggests that angiogenesis and inflammation frequently occur together, but the pathophysiologic relevance of angiogenesis in the perpetuation of chronic inflammation has been limited to animal studies [80,81,81,82]. Further studies should be designed to specifically investigate the role of angiogenesis in the chronically inflamed tissues of human IBD.

Evidence for ischaemia in the chronically inflamed IBD intestine

  1. Top of page
  2. Abstract
  3. Introduction
  4. Evidence for hyperaemia in the chronically inflamed IBD intestine
  5. Evidence for ischaemia in the chronically inflamed IBD intestine
  6. Unifying hypothesis for altered vascular physiology in IBD
  7. References

Diminished mucosal perfusion – intraoperative and endoscopic studies

In IBD, intestinal vascular damage has been demonstrated as an early pathologic finding that precedes mucosal ulceration. Damage is often greatest in areas where vessels penetrate through the muscularis propria and in regions of dense angiogenesis observed in distal areas of the mucosal circulation. Funayama et al.[83] investigated remodelling in the intestinal micro-circulation from CD resected bowel using tissue histometry and suggested that circulatory disturbance occurred in the early stage in CD, leading to increased vascular resistance in the area between the deep submucosal and the distal mesenteric arteries, possibly contributing to ischaemia. Furthermore, Wakefield et al.[84] identified occlusive fibrinoid lesions in the small arteries and arterioles supplying CD-affected areas of intestine that were not demonstrated in uninvolved areas of bowel using scanning electron micrographs of corrosion microcasts. Morphologically, the chronically inflamed micro-vessels were tapered and stenosed compared with vessels from areas of uninvolved CD and control bowel. Taken together, these studies suggest that the microvascular anatomy undergoes vascular remodelling and plays a role in the pathogenesis of chronic inflammatory lesions, with the extent of vascular damage correlating with the severity of intestinal injury.

Attempts to characterize alterations in intestinal blood flow in IBD have been utilized both direct and indirect methods. In 1977, Hulten et al. demonstrated in chronically inflamed tissues (both chronically active and quiescent disease) diminished gut perfusion compared with controls, which correlated with histological evidence of persistent ulceration and intestinal fibrosis [14]. Angerson et al. demonstrated similar findings using endoscopic Doppler laser flowmetry, where chronically inflamed CD bowel demonstrated significantly decreased perfusion [32]. Similar findings were demonstrated by Tateishi and colleagues using laser Doppler flowmetry intra-operatively in CD patients undergoing resection [40]. These observations have consistently demonstrated that the most severe decrease in vascular perfusion is found in association with fibrotic strictures in patients with longstanding CD [32].

This potential contribution of mucosal ischaemia to chronic inflammation in IBD was evaluated by Wakefield et al. using scanning electron micrographs of corrosion microcasts following bowel resection [84]. They identified occlusive fibrinoid lesions in the arterioles supplying areas of intestine affected by CD, which were not found in uninvolved areas of bowel. This was described as a ‘granulomatous vasculitis’, with a histological appearance characteristic of prolonged disruption in the local vascular supply leading to microinfarction. Importantly, microvascular damage was an early pathologic finding that preceded the development of mucosal ulceration.

Microvascular dysfunction in IBD arterioles – microvascular physiologic studies

Refractory, poorly healing wounds such as foot and leg ulcers in patients with peripheral vascular disease and longstanding diabetes mellitus are frequently ischaemic in origin and have been linked to microvascular dysfunction [85–90]. In IBD intestine, similar poor healing and refractory inflammatory ulcerations occur in the gut mucosa, consistent with tissue hypoperfusion of an ischaemic etiology. This raises the question of whether impaired vasodilation and chronic hypoperfusion are responsible for the progression of disease in IBD. Based on this hypothesis, Hatoum et al.[91] directly examined the vasodilator responses in human intestinal microvessels by measuring in vitro vasodilator capacity in response to acetylcholine (Ach; endothelial-dependent vasodilator) from suspended and perfused 100–150-micron diameter intestinal arterioles isolated from IBD and control (non-IBD) specimens following intestinal resection. Non-IBD intestinal arterioles dilated dose-dependently to Ach, whilst chronically inflamed IBD arterioles (both CD and UC) demonstrated a diminished vasodilatory capacity to Ach [non-IBD microvessels maximal dilation (MD): 82 ± 2%, n = 34 compared with IBD microvessels MD: 15 ± 2%, n = 33, respectively; P ≤ 0·05]. This decreased vasodilator capacity was directly related to a loss of nitric oxide (NO) dependent function. The same vessels were found to be heavily dependent on cyclo-oxygenase (COX)-derived vasodilator compounds to maintain vascular tone and dilator capacity to Ach. The use of indomethacin, a nonselective COX isoforms inhibitor, decreased vasodilation of non-IBD vessels to Ach by approximately 40%, whilst in IBD arterioles it resulted in frank vasoconstriction [91]. The mechanism of the impaired NO-mediated dilation may have involved excess production of oxidative stress, as these compounds were measured by intravital dyes in IBD but not control arterioles [91].

Similar results were published recently using animal models of dextran-sodium sulphate (DSS) induced colonic inflammation. Mori et al. reported the time-course of changes in colonic blood perfusion and the mechanisms that may underlie these changes in blood flow. They reported a significant reduction (18–30%) in blood flow in small arterioles (< 40 µm diameter) on days four through six of DSS colitis in response to bradykinin. In addition, they found that NAD(P)H oxidase-derived superoxide plays a major role in the induction of the inflammation-induced endothelium-dependent arteriolar dysfunction [92].

Loss of endothelial generation of NO in IBD endothelial cells

Early studies into the potential role of the endothelium in IBD pathogenesis focused on histological evaluation, characterizing the morphology of the microvasculature in chronically inflamed intestine. Dvorak et al. evaluated CD intestinal specimens using transmission electron microscopy, and demonstrated endothelial cell abnormalities, characterized by loss of monolayer integrity with tissue oedema and extravasation of red blood cells, focal venular endothelial necrosis adjacent to areas of undamaged endothelial cells as well as endothelial cell hypertrophy [3]. To more fully define the contribution of microvascular endothelial cells in chronic intestinal inflammation, Binion et al. developed protocols for the routine isolation and long-term culture of pure populations of human intestinal microvascular endothelial cells (HIMECs) from small and large intestinal resections. Endothelial cultures were generated from areas of chronically inflamed and uninvolved CD and UC intestine. Human intestinal microvascular endothelial cells isolated from both chronically inflamed CD and UC demonstrated a significantly enhanced capacity to adhere leukocytes, compared with control HIMEC cultures. The phenomenon of leukocyte hyperadhesion was only present in chronically inflamed IBD HIMECs, as cultures derived from uninvolved areas in close proximity failed to demonstrate increased leukocyte binding [93]. The mechanisms underlying leukocyte hyperadhesion in the chronically inflamed IBD HIMECs did not appear to involve altered patterns of cell adhesion molecule expression, but instead were linked to reduced NO production [94,95]. The NO exerts a potent anti-inflammatory effect within the vasculature, down-regulating the activation of vascular endothelial cells as well as their capacity to bind circulating leukocytes (normally an early, rate-limiting step in the inflammatory process). Control HIMECs displayed distinct patterns of NO generation through both constitutive endothelial nitric oxide synthase (eNOS; NOS3) as well as inducible NOS (iNOS; NOS2). Inhibition of iNOS function in control HIMECs produced increased patterns of leukocyte binding, which were similar to IBD HIMECs. Investigation of the mechanisms of reduced NO generation in the IBD HIMECs confirmed that a loss of iNOS gene transcription and expression resulted from elevations in cytokines and lipopolysaccharides.

Enhanced vasoconstrictor products in IBD intestine

Additional evidence for mucosal hypoperfusion in CD and UC comes from studies investigating specific vasoconstrictor peptides. The endothelin peptides (ET-1, ET-2 and ET-3) are potent and long-acting vasoconstrictors that have been implicated as causative agents in a number of pathological states [96,97]. Because IBD micro-vessels often display heightened vasomotor tone, Murch et al. performed initial studies demonstrating increased levels of endothelins in IBD. Both ET-1 and ET-2 were found to be increased in the colonic mucosa from patients with CD and UC [98]. This observation provided an important link between the hypotheses that immunological hypersensitivity [99] and vascular abnormalities [100,101] contributed to the pathophysiology of IBD. Interestingly, several of the pro-inflammatory cytokines [102,103] can stimulate production of endothelin's [104,105]. What Klemm et al. have shown indicates that administration of tumour necrosis factor-alpha and interleukin-2 to anaesthetized rats caused a marked elevation in the circulating plasma level of ET-1 and a very pronounced ET-1-dependent coronary vasoconstriction. In addition, using rats suffering from adjuvant polyarthritis, in which there is marked joint inflammation and associated cytokine production, there was dramatic increases in coronary perfusion pressure which were absent when rats were treated with an endothelin receptor antagonist.

Despite these earlier observations, other investigators have not confirmed an increase in tissue ET-1 and ET-2 in IBD, with Rachmilewtz et al. actually reporting reduced levels of both mediators in UC [106]. These observations suggest that cytokines could induce the production of endothelin and promote vasoconstriction which may lead to tissue damage. Furthermore, despite the presence of endothelin binding sites to ET-1 in the colonic neural plexus and mucosa [107,108], the authors believe that further studies are needed to test the relative expression and roles of the individual endothelin isopeptides within the human gastrointestinal tract.

Thromboxane A2 is a pro-inflammatory eicosanoid derived from isomerisation of prostaglandin H2 by thromboxane synthase. Thromboxane A2 has a very short half life and is rapidly metabolized to the more stable product, thromboxane B2[109]. Mucosal production of thromboxane is increased, both in the spontaneous model of colitis [110,111] and in colitis induced by exogenous agents [112–114]. Within human IBD, thromboxane production in cultured isolated intestinal epithelial cells from patients with UC and those with CD is increased [115,116]. Additionally, in active colonic tissue homogenates from patients with UC [117,118] and in cultured biopsies from both patients with UC or CD excess thromboxane production was observed [119–121]. Moreover, rectal dialysis in patients with UC and CD showed increased rectal mucosal production of thromboxane in active disease in vivo[122–125]. In vitro, studies have shown that thromboxane has pro-inflammatory actions and induces the activation of neutrophils [126], the production of leukotriene B4 [127] and enhances neutrophil adhesion to the endothelium [128] with subsequent diapedesis [129]. Furthermore, it induces apoptosis [130], modulates T-cell function [131] and induces vasoconstriction [132] and platelet aggregation [109]. The platelet aggregates have been identified in the capillaries of inflamed rectal biopsies in IBD [133], and microvascular thrombosis has been proposed as an early pathogenic factor in CD [101]. Therefore, thromboxane can perpetuate ischaemic injury and thereby play a key role in the pathogenesis of IBD.

Clinical response to pharmacological vasoconstrictors in IBD: non-steroidal anti-inflammatory agents

It has been documented that nonsteroidal anti-inflammatory drugs (NSAIDs) can have deleterious effects on small bowel and colonic mucosa in addition to the well-known adverse effects on the upper gastrointestinal tract [134–140]. The clinical manifestations of NSAID-associated small and large bowel tract toxicity are extensive and include diarrhoea, abdominal pain, blood and protein loss, colitis and perforation. The influence of NSAIDs has been reported to cause the initial onset of IBD and to be associated with reactivation of quiescent disease. This conclusion has been based largely on case reports and small series of patients [134–140]. More recently, authors have noted a higher than expected use of NSAIDs among patients admitted to the hospital for flares of IBD [140], leading some physicians to recommend that IBD patients strictly avoid use of NSAIDs [135,141]. The mechanism by which NSAIDs may provoke inflammatory bowel disease is not clear, but may involve a mechanism of altered arachidonic acid metabolism similar to that of NSAID-induced enterocolitis that is not related to IBD [142–145]. Some prostaglandins, end products of the cyclooxygenase pathway, serve a protective role in the gut [146–149] and NSAIDs inhibit their formation. Similar findings have been seen in an animal model of experimental colitis, which demonstrated marked elevation of cyclooxygenase-2 mRNA and increased prostaglandin synthesis by the colon. Treatment with selective cyclooxygenase-2 inhibitors resulted in exacerbation of inflammation-associated colonic injury and perforation leading to early death in the treated group [150].

Specific inhibition of thromboxane synthase, but not cyclooxygenase or prostacyclin synthase, leads to reduced formation of thromboxane, overproduction of prostaglandins I2, E2 and D2 and no change in leukotriene production. Ridogrel (thromboxane synthase inhibitor and receptor antagonist) [151–153] ameliorates experimental colitis in animals and has shown promise in preliminary studies in patients with UC [113,154]. Furthermore, a pilot open-label trial with a different thromboxane synthase inhibitor and receptor antagonist, picotamide, also suggested an improvement in CD activity index after 6 weeks of treatment in nine patients with active CD [155–157]. In contrast, studies that failed to achieve sufficient inhibition of thromboxane synthesis and of platelet function demonstrated no clinical improvement [155,158]. If overproduction of mucosal thromboxane and excessive platelet activation are of major pathogenic importance in CD, confirmation of this hypothesis would depend on new comprehensive large, randomized, controlled clinical trials using different agents and doses to achieve potent inhibition of the synthesis and/or actions of this eicosanoid.

Unifying hypothesis for altered vascular physiology in IBD

  1. Top of page
  2. Abstract
  3. Introduction
  4. Evidence for hyperaemia in the chronically inflamed IBD intestine
  5. Evidence for ischaemia in the chronically inflamed IBD intestine
  6. Unifying hypothesis for altered vascular physiology in IBD
  7. References

The evidence presented in this review strongly suggests that the vasculature plays a central role in the pathology of human inflammatory bowel disease. In addition to the known abnormalities of leukocyte recruitment, the physiology of vascular perfusion is fundamentally altered in IBD. These data demonstrate that in chronic intestinal inflammation there are alterations in vascular perfusion, which may be dependent on location of the vascular bed (i.e. mucosal vs. serosal surface) and may be integrally linked to the phase of the disease (early disease is characterized by hyperaemia, while long-standing, remodelled bowel is associated with diminished vascular perfusion in the mucosa). Clearly, a unifying hypothesis is needed regarding the vascular pathophysiology that accounts for the mesenteric, serosal and bowel wall hyperaemia, which exists in concert with mucosal ischaemia in IBD.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Evidence for hyperaemia in the chronically inflamed IBD intestine
  5. Evidence for ischaemia in the chronically inflamed IBD intestine
  6. Unifying hypothesis for altered vascular physiology in IBD
  7. References
  • 1
    Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 2001;8 (5):283301.
  • 2
    Laroux FS. Mechanisms of inflammation: the good, the bad and the ugly. Front Biosci 2004;9: 315662.
  • 3
    Cotran RS. Robbins Pathologic Basis of Disease, 5th edn. Philadelphia: W.B. Saunders Company;1994.
  • 4
    Fazio VW, Jones IT. Standard Surgical treatment of Crohn's disease of small intestine and ileocolitis. In: LeeECG, NolanDJ, editors. Surgery of Inflammatory Bowel Disease. Edinburgh: Churchill Livingstone;1987: 823848.
  • 5
    Weakley FL, Turnbull RB. Recognition of regional ileitis in the operating room. Dis Colon Rectum 1971;14 (1):1723.
  • 6
    Borley NR, Mortensen NJ, Jewell DP, Warren BF. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link. J Pathol 2000;190 (2):196202.
  • 7
    Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79 (9):9558.
  • 8
    Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117 (1):7381.
  • 9
    Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003;27 (11):98791.
  • 10
    Boydstun JS Jr, Gaffey TA, Bartholomew LG. Clinicopathologic study of nonspecific ulcers of the small intestine. Dig Dis Sci 1981;26 (10):9116.
  • 11
    Lawrason FD, Alpert E, Mohr FL, McMahon FG. Ulcerative-obstructive lesions of the small intestine. JAMA 1965;191: 6414.
  • 12
    Englmeier KH, Herpers R, Jacoby RS, Zwiebel FM. A method for the estimation of the hemoglobin distribution in gastroscopic images. Int J Biomed Comput 1996;41 (3):15365.
  • 13
    Pereira JM, Sirlin CB, Pinto PS, Casola G. CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. Radiographics 2005;25 (1):6985.
  • 14
    Hulten L, Lindhagen J, Lundgren O, Fasth S, Ahren C. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology 1977;72 (3):38896.
  • 15
    Bacaner MB. Quantitative measurement of regional colon blood flow in the normal and pathological human bowel. Gastroenterology 1966;51 (5):76477.
  • 16
    Ludwig D, Schwarting K, Korbel CM, Bruning A, Schiefer B, Stange EF. The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. J Hepatol 1998;28 (4):6318.
  • 17
    McLean A. Transabdominal bowel sonography in Crohn's disease. Gut 1999;44 (1):67.
  • 18
    Muller AF. Role of duplex Doppler ultrasound in the assessment of patients with post-prandial abdominal pain. Gut 1992;33 (4):4605.
  • 19
    Maconi G, Parente F, Bollani S, Cesana B, Bianchi PG. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol 1996;91 (8):16049.
  • 20
    Maconi G, Imbesi V, Bianchi PG. Doppler ultrasound measurement of intestinal blood flow in inflammatory bowel disease. Scand J Gastroenterol 1996;31 (6):5903.
  • 21
    Van Oostayen JA, Wasser MN, Griffioen G, Van Hogezand RA, Lamers CB, De RA. Activity of Crohn's disease assessed by measurement of superior mesenteric artery flow with Doppler ultrasound. Neth J Med 1998;53 (6):S3S8.
  • 22
    Van Oostayen JA, Wasser MN, Griffioen G, Van Hogezand RA, Lamers CB, De RA. Diagnosis of Crohn's ileitis and monitoring of disease activity: value of Doppler ultrasound of superior mesenteric artery flow. Am J Gastroenterol 1998;93 (1):8891.
  • 23
    Van Oostayen JA, Wasser MN. Use of Doppler ultrasound in Crohn's disease. Gut 2000;47 (1):156.
  • 24
    Van Oostayen JA, Wasser MJ. Use of Doppler ultrasound of the SMA for Crohn's disease activity evaluation in clinical practice. Clin Radiol 2002;57 (6):537.
  • 25
    Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease. Gut 1999;44 (1):1127.
  • 26
    Sonnenberg A, Erckenbrecht J, Peter P, Niederau C. Detection of Crohn's disease by ultrasound. Gastroenterology 1982;83 (2):4304.
  • 27
    Bolondi L, Gaiani S, Brignola C, Campieri M, Rigamonti A, Zironi G et al. Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol 1992;27 (6):5017.
  • 28
    May CN. Prolonged systemic and regional haemodynamic effects of intracerebroventricular angiotensin II in conscious sheep. Clin Exp Pharmacol Physiol 1996;23 (10–11):87884.
  • 29
    Iwao T, Toyonaga A, Sato M, Oho K, Sakai T, Tayama C et al. Effect of posture-induced blood volume expansion on systemic and regional hemodynamics in patients with cirrhosis. J Hepatol 1997;27 (3):48491.
  • 30
    Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci (Lond) 1992;83 (2):1718.
  • 31
    Ulrich-Baker MG, Hollwarth ME, Kvietys PR, Granger DN. Blood flow responses to small bowel resection. Am J Physiol 1986;251 (6 Part 1):G815G822.
  • 32
    Angerson WJ, Allison MC, Baxter JN, Russell RI. Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease. Gut 1993;34 (11):15314.
  • 33
    Worlicek H, Lutz H, Heyder N, Matek W. Ultrasound findings in Crohn's disease and ulcerative colitis: a prospective study. J Clin Ultrasound 1987; 15 (3):15363.
  • 34
    Worlicek H. Sonography of the small and large intestine – differential diagnosis of wall thickening. Bildgebung 1987;56 (1):2734.
  • 35
    Kimmey MB, Wang KY, Haggitt RC, Mack LA, Silverstein FE. Diagnosis of inflammatory bowel disease with ultrasound: An in vitro study. Invest Radiol 1990;25 (10):108590.
  • 36
    Heyne R, Rickes S, Bock P, Schreiber S, Wermke W, Lochs H. Non-invasive evaluation of activity in inflammatory bowel disease by power Doppler sonography. Z Gastroenterol 2002;40 (3):1715.
  • 37
    Goldberg BB, Liu JB, Burns PN, Merton DA, Forsberg F. Galactose-based intravenous sonographic contrast agent: experimental studies. J Ultrasound Med 1993;12 (8):46370.
  • 38
    Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: a new era in ultrasound. BMJ 2001;322 (7296):12225.
  • 39
    Di Sabatino A, Fulle I, Ciccocioppo R, Ricevuti L, Tinozzi FP, Tinozzi S et al. Doppler enhancement after intravenous levovist injection in Crohn's disease. Inflamm Bowel Dis 2002;8 (4):2517.
  • 40
    Tateishi S, Arima S, Futami K. Assessment of blood flow in the small intestine by laser Doppler flowmetry: comparison of healthy small intestine and small intestine in Crohn's disease. J Gastroenterol 1997t;32 (4):45763.
  • 41
    Crohn BB, Ginsberg L, Oppenheimer GD. Regional ilietis: a clinical and pathological entity. JAMA 1932;99: 13239.
  • 42
    Futagami Y, Haruma K, Hata J, Fujimura J, Tani H, Okamoto E et al. Development and validation of an ultrasonographic activity index of Crohn's disease. Eur J Gastroenterol Hepatol 1999;11 (9):100712.
  • 43
    Limberg B, Osswald B. Diagnosis and differential diagnosis of ulcerative colitis and Crohn's disease by hydrocolonic sonography. Am J Gastroenterol 1994;89 (7):10517.
  • 44
    Reimund JM, Jung-Chaigneau E, Chamouard P, Wittersheim C, Duclos B, Baumann R. Diagnostic value of high resolution sonography in Crohn's disease and ulcerative colitis. Gastroenterol Clin Biol 1999;23 (6–7):7406.
  • 45
    Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med 2002;21 (4):37582.
  • 46
    Laghi A, Paolantonio P, Iafrate F, Borrelli O, Dito L, Tomei E et al. MR of the small bowel with a biphasic oral contrast agent (polyethylene glycol): technical aspects and findings in patients affected by Crohn's disease. Radiol Med (Torino) 2003;106 (1–2):1827.
  • 47
    Haber HP, Busch A, Ziebach R, Stern M. Bowel wall thickness measured by ultrasound as a marker of Crohn's disease activity in children. Lancet 2000;355 (9211):123940.
  • 48
    Kettritz U, Shoenut JP, Semelka RC. MR imaging of the gastrointestinal tract. Magn Reson Imaging Clin N Am 1995;3 (1):8798.
  • 49
    D’Arienzo A, Scaglione G, Bennato R, Manguso F, Vicinanza G, Belfiore G et al. The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil. Am J Gastroenterol 2001;96 (2):4816.
    Direct Link:
  • 50
    Mayer D, Reinshagen M, Mason RA, Von Muche RTC, Eckelt D, Adler G et al. Sonographic measurement of thickened bowel wall segments as a quantitative parameter for activity in inflammatory bowel disease. Z Gastroenterol 2000;38 (4):295300.
  • 51
    Risau W. Mechanisms of angiogenesis. Nature 1997;386 (6626):6714.
  • 52
    Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43: 175203.
  • 53
    Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford) 1999;38 (2):10312.
  • 54
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1 (1):2731.
  • 55
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86 (3):35364.
  • 56
    Polverini PJ. Role of the macrophage in angiogenesis-dependent diseases. EXS 1997;79: 1128.
  • 57
    Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98 (2):14757.
  • 58
    Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999;5 (5):495502.
  • 59
    Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 1999;237: 13358.
  • 60
    Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5 (12):135964.
  • 61
    Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR, Hart CE et al. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995;73 (3):33946.
  • 62
    Qu Z, Liebler JM, Powers MR, Galey T, Ahmadi P, Huang XN et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995;147 (3):56473.
  • 63
    Walsh DA, Wade M, Mapp PI, Blake DR. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 1998;152 (3):691702.
  • 64
    Walsh DA, Mapp PI. Joint physiology and synovial cell proliferation. Br J Rheumatol 1998;37 (9):10323.
  • 65
    Walsh DA, Rodway HA, Claxson A. Vascular turnover during carrageenan synovitis in the rat. Lab Invest 1998;78 (12):151321.
  • 66
    Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol 2005;83 (2):10618.
    Direct Link:
  • 67
    Hatton MW, Southward SM, Legault KJ, Ross BL, Clarke BJ, Bajzar L et al. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin (ogen) fragments contain antiangiogenic activity. J Lab Clin Med 2004;143 (4):24154.
  • 68
    Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003;95 (22):166073.
  • 69
    Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D et al. Generation of biologically active angiostatin kringle 1–3 by activated human neutrophils. J Immunol 2002;168 (11):5798804.
  • 70
    Collin-Osdoby P, Rothe L, Bekker S, Anderson F, Huang Y, Osdoby P. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 2002;17 (10):185971.
  • 71
    Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004; 93 (1):3943.
  • 72
    Okada F. Inflammation and free radicals in tumor development and progression. Redox Rep 2002;7 (6):35768.
  • 73
    Crivellato E, Ribatti D. Involvement of mast cells in angiogenesis and chronic inflammation. Curr Drug Targets Inflamm Allergy 2005;4 (1):911.
  • 74
    Milkiewicz M, Brown MD, Egginton S, Hudlicka O. Association between shear stress, angiogenesis, and VEGF in skeletal muscles in vivo. Microcirculation 2001;8 (4):22941.
  • 75
    Cullen JP, Sayeed S, Sawai RS, Theodorakis NG, Cahill PA, Sitzmann JV et al. Pulsatile flow-induced angiogenesis: role of G (i) subunits. Arterioscler Thromb Vasc Biol 2002;22 (10):16106.
  • 76
    Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003;23 (7):114351.
  • 77
    Saito S, Tsuno NH, Sunami E, Hori N, Kitayama J, Kazama S et al. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol 2003;38 (3):22937.
  • 78
    Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001;96 (3):8228.
  • 79
    Danese S, Sans M, Spencer D, Beck I, Plunkett M, Donate F et al. Starving the inflamed gut: Angiogenesis blockade as a novel therapeutic approach to experimental colitis. Gastroenterology 2005;128 (4): A-40 (Abstract).
  • 80
    Stupack DG, Storgard CM, Cheresh DA. A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res 1999;32 (5):57381.
  • 81
    Jackson JR, Bolognese B, Kircher CH, Marshall LA, Winkler JD. Modulation of angiogenesis in a model of chronic inflammation. Inflamm Res 1997;46 (Suppl. 2):S12930.
  • 82
    Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32 (9):106573.
  • 83
    Funayama Y, Sasaki I, Naito H, Fukushima K, Matsuno S, Masuda T. Remodeling of vascular wall in Crohn's disease. Dig Dis Sci 1999;44 (11):231923.
  • 84
    Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 100 (5 Part 1):127987.
  • 85
    Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC. Restoring vascular nitric oxide formation by 1-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32 (5):133644.
  • 86
    Kerstein MD. The non-healing leg ulcer: peripheral vascular disease, chronic venous insufficiency, and ischemic vasculitis. Ostomy Wound Manage 1996;42 (10A Suppl.):19S35S.
  • 87
    Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compression pump for non-healing wounds in patients with limb ischemia. The Mayo Clinic experience (1998–2000). Int Angiol 2002;21 (4):3606.
  • 88
    Flynn MD, Tooke JE. Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabet Med 1992;9 (4):3209.
  • 89
    Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998;47 (3):45763.
  • 90
    Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003;20 (4):25568.
  • 91
    Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125 (1):5869.
  • 92
    Mori M, Stokes KY, Vowinkel T, Watanabe N, Elrod JW, Harris NR et al. Colonic blood flow responses in experimental colitis: time-course and underlying mechanisms. Am J Physiol Gastrointest Liver Physiol 2005; in press.
  • 93
    Binion DG, West GA, Volk EE, Drazba JA, Ziats NP, Petras RE et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352 (9142):17426.
  • 94
    Binion DG, Rafiee P, Ramanujam KS, Fu S, Fisher PJ, Rivera MT et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 2000;29 (9):8818.
  • 95
    Binion DG, Fu S, Ramanujam KS, Chai YC, Dweik RA, Drazba JA et al. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol 1998;275 (3 Part 1):G592603.
  • 96
    Haynes WG, Davenport AP, Webb DJ. Endothelin: progress in pharmacology and physiology. Trends Pharmacol Sci 1993;14 (6):2258.
  • 97
    Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46 (3):325415.
  • 98
    Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 1992;339 (8790):3815.
  • 99
    Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999;5 (1):4460.
  • 100
    Hamilton MI, Dick R, Crawford L, Thompson NP, Pounder RE, Wakefield AJ. Is proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery? Lancet 1995;345 (8951):68890.
  • 101
    Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;2 (8671):105762.
  • 102
    Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95 (2):35967.
  • 103
    Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106 (6):145566.
  • 104
    Klemm P, Warner TD, Corder R, Vane JR. Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J Cardiovasc Pharmacol 1995;26 (Suppl. 3):S41921.
  • 105
    Warner TD, Klemm P. What turns on the endothelins? Inflamm Res 1996;45 (2):513.
  • 106
    Rachmilewitz D, Eliakim R, Ackerman Z, Karmeli F. Colonic endothelin-1 immunoreactivity in active ulcerative colitis. Lancet 1992;339 (8800):1062.
  • 107
    Inagaki H, Bishop AE, Yura J, Polak JM. Localization of endothelin-1 and its binding sites to the nervous system of the human colon. J Cardiovasc Pharmacol 1991;17 (Suppl. 7):S4557.
  • 108
    Inagaki H, Bishop AE, Escrig C, Wharton J, Len-Mersh TG, Polak JM. Localization of endothelin like immunoreactivity and endothelin binding sites in human colon. Gastroenterology 1991;101 (1):4754.
  • 109
    Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72 (8):29948.
  • 110
    Clapp N, Henke M, Hansard R, Carson R, Walsh R, Widomski D et al. Inflammatory mediator changes in cotton-top tamarins (CTT) after SC-41930 anti-colitic therapy. Agents Actions 1993;39: C810.
  • 111
    Clapp N, Henke M, Hansard R, Carson R, Fretland D. Anti-colitic efficacy of SC-41930 in colitic cotton-top tamarins. Agents Actions 1993;39: C368.
  • 112
    Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats: Similarity to human inflammatory bowel disease. Gastroenterology 1985;88 (1 Part 1): 5563.
  • 113
    Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990;98 (2):26977.
  • 114
    Kitsukawa Y, Saito H, Suzuki Y, Kasanuki J, Tamura Y, Yoshida S. Effect of ingestion of eicosapentaenoic acid ethyl ester on carrageenan-induced colitis in guinea pigs. Gastroenterology 1992;102 (6):185966.
  • 115
    Zifroni A, Treves AJ, Sachar DB, Rachmilewitz D. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983;24 (7):65964.
  • 116
    Rampton DS, Collins CE. Review article: thromboxanes in inflammatory bowel disease – pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993;7 (4):35767.
  • 117
    Boughton-Smith NK, Hawkey CJ, Whittle BJ. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa. Gut 1983;24 (12):117682.
  • 118
    Boughton-Smith NK, Whittle BJ. Stimulation and inhibition of prostacyclin formation in the gastric mucosa and ileum in vitro by anti-inflammatory agents. Br J Pharmacol 1983;78 (1):17380.
  • 119
    Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985;30 (12):11615.
  • 120
    Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 1985;89 (5):116288.
  • 121
    Hawkey CJ. Gastroduodenal problems associated with non-steroidal, anti-inflammatory drugs (NSAIDs). Scand J Gastroenterol Suppl 1993;200: 945.
  • 122
    Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988;29 (10):131621.
  • 123
    Lauritsen K, Rask-Madsen J. Prostaglandin analogues. Baillieres Clin Gastroenterol 1988;2 (3):6218.
  • 124
    Lauritsen K, Staerk LL, Bukhave K, Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 1988;29 (7):97482.
  • 125
    Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988;95 (1):117.
  • 126
    Kitchen EA, Boot JR, Dawson W. Chemotactic activity of thromboxane B2, prostaglandins and their metabolites for polymorphonuclear leucocytes. Prostaglandins 1978;16 (2):23944.
  • 127
    Goldman G, Welbourn R, Valeri CR, Shepro D, Hechtman HB. Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation. Microvasc Res 1991;41 (3):36775.
  • 128
    Wiles ME, Welbourn R, Goldman G, Hechtman HB, Shepro D. Thromboxane-induced neutrophil adhesion to pulmonary microvascular and aortic endothelium is regulated by CD18. Inflammation 1991;15 (3):18199.
  • 129
    Doukas J, Hechtman HB, Shepro D. Endothelial-secreted arachidonic acid metabolites modulate polymorphonuclear leukocyte chemotaxis and diapedesis in vitro. Blood 1988;71 (3):7719.
  • 130
    Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O et al. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 1993;178 (5):182530.
  • 131
    Kelly JP, Johnson MC, Parker CW. Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol 1979;122 (4):156371.
  • 132
    Zipser RD, Patterson JB, Kao HW, Hauser CJ, Locke R. Hypersensitive prostaglandin and thromboxane response to hormones in rabbit colitis. Am J Physiol 1985;249 (4 Part 1):G45763.
  • 133
    Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M et al. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992;21 (2):12733.
  • 134
    Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107 (4):5136.
  • 135
    Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J 1981;57 (667):2979.
  • 136
    Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1984;288 (6412):238.
  • 137
    Pearson DJ, Stones NA, Bentley SJ. Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. Br Med J (Clin Res Ed) 1983;287 (6406):1675.
  • 138
    Rutherford D, Stockdill G, Hamer-Hodges DW, Ferguson A. Proctocolitis induced by salicylate. Br Med J (Clin Res Ed) 1984;288 (6419):794.
  • 139
    Shanahan F, Targan S. Sulfasalazine and salicylate-induced exacerbation of ulcerative colitis. N Engl J Med 1987;317 (7):455.
  • 140
    Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992;152 (3):62532.
  • 141
    Schwartz HA. Lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs. J Rheumatol 1981;8 (6):9524.
  • 142
    Bjarnason I, Zanelli G, Smith T, Smethurst P, Price AB, Gumpel MJ et al. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol Suppl 1987;64: 5562.
  • 143
    Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93 (3):4809.
  • 144
    Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut 1984;25 (12):1399413.
  • 145
    Rampton DS, Barton TP. Are prostaglandins cytoprotective in the human large intestine? The effect of indomethacin on rectal mucosal function and prostaglandin E2 release in vivo. Agents Actions 1984;14 (5–6):7158.
  • 146
    Bjarnason I, Smethurst P, Clark P, Menzies I, Levi J, Peters T. Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol Suppl 1989;164: 97102.
  • 147
    Bjarnason I, Macpherson A. The changing gastrointestinal side effect profile of non-steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol Suppl 1989;163: 5664.
  • 148
    Scadding G, Bjarnason I, Brostoff J, Levi AJ, Peters TJ. Intestinal permeability to 51Cr-labelled ethylenediaminetetraacetate in food-intolerant subjects. Digestion 1989;42 (2):1049.
  • 149
    Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77 (4 Part 1):7617.
  • 150
    Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112 (3):100016.
  • 151
    De CF, Beetens J, De Chaffoy de CD, Freyne E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule – I. Biochemical profile in vitro. Thromb Haemost 1989;61 (1):3542.
  • 152
    De CF, Beetens J, Van de WA, Vercammen E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule – II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989;61 (1):439.
  • 153
    De CF, Beetens J, De Chaffoy de CD, Vercammen E, Freyne E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule. Prog Clin Biol Res 1989;301: 56772.
  • 154
    Casellas F, Papo M, Guarner F, Antolin M, Segura RM, Armengol JR et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7 (3):2216.
  • 155
    Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease – pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 1997;11 (2):23747.
  • 156
    Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994;106 (4):8405.
  • 157
    Collins CE, Benson MJ, Burnham WR, Rampton DS. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. Aliment Pharmacol Ther 1996;10 (3):31520.
  • 158
    Carty E, MacEy M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14 (6):80717.